Treatments for Inflammation Scientists
Treatments for Inflammation team – lead scientists
Dr. Daniel Muruve Ph. D
Chief Science Officer (CSO)
Co-Founder
Daniel Muruve is a Professor in the Department of Medicine at the University of Calgary. He graduated from the Faculty of Medicine at the University of Manitoba in 1989 and has undertaken extensive post-graduate medical and scientific training over 10 years at the University of Calgary, Harvard University and the University of Lausanne. Dr. Muruve is a certified kidney specialist and a basic scientist with expertise in the biology of kidney disease and the molecular basis of inflammation and the immune system. He is an AHFMR Clinical Senior Scholar and holds a Canada Research Chair in Inflammation and Kidney Disease.
Dr. Justin Macdonald Ph. D
Justin Macdonald is a Professor in the Department of Biochemistry & Molecular Biology at the University of Calgary. He obtained his Ph.D. at Carleton University and his post-doctoral training at the University of Virginia and Duke University. His expertise is in smooth muscle contractile physiology, biochemistry and proteomics. He currently holds a Canada Research Chair in Smooth Muscle Pathophysiology.
Dr. Paul Beck Ph. D
Paul Beck is a Professor in the Department of Medicine at the University of Calgary. He first obtained his Ph.D. at Queens University and followed this up by a medical degree at the University of Calgary. Dr. Beck has more than 10 years of post-graduate education at the University of Calgary and Harvard University. He is a certified clinical specialist in Gastroenterology and a basic scientist with expertise in the cellular and molecular biology of inflammation and how it pertains to inflammatory bowel disease and the gastrointestinal tract.
Dr. Arthur Lau Ph. D
Arthur Lau is a Project Manager at Arch Biopartners and a Research Scientist in Dr. Daniel Muruve’s research program. He completed a B.Sc. with Honours at the University of Toronto and a Ph.D. at the University of Western Ontario with a focus on kidney transplantation and immunology. As a postdoctoral fellow at the University of Calgary under the mentorship of Dr. Muruve, he continued his research on acute kidney injury and immunology including publications describing the use of LSALT peptide in renal disease. His current research focus is on elucidating mechanisms of immune surveillance in the kidney and developing therapeutics against acute kidney injury. Arthur joined the Arch Biopartners’ team as a Project Manager primarily managing the development of the LSALT peptide/Metablok portfolio and its related technologies.
